21155 ⎘
Medicinal preparations containing antigens or antibodies; Antibodies ; Immunoglobulins; Immune serum, e.g. antilymphocytic serum Stabilisation, fragmentation
BINDING MEMBERS TO TNF ALPHA
#302Methods of inactivating viral contaminants
#303LIQUID PHARMACEUTICAL COMPOSITION
#304Anti-IL31RA antibody-containing formulations
#305Stable Aqueous Formulations of Natalizumab
#306ANTI-IL-23 ANTIBODIES
#307Anti-RSV monoclonal antibody formulation
#308LIQUID PHARMACEUTICAL COMPOSITION
#309COMPOSITIONS OF FCRN ANTIBODIES AND METHODS OF USE THEREOF
#310IMMUNOGLOBULIN FORMULATION AND METHOD OF PREPARATION THEREOF
#311METHOD FOR THE PRODUCTION OF FREEZE-DRIED PELLETS COMPRISING AN ANTI-COAGULATION FACTOR XIa (FXIa) ANTIBODY
#312FORMULATIONS OF ANTIBODY
#313Human antibodies, pharmaceutical compositions and methods
#314AQUEOUS PHARMACEUTICAL FORMULATIONS
#315Compositions comprising an anti-LAG-3 antibody or an anti-LAG-3 antibody and an anti-PD-1 or anti-PD-L1 antibody
#316High concentration antibody formulations
#317Anti-BAFFR antibody formulations and methods of use thereof
#318Methods for quantitating individual antibodies from a mixture
#319Liquid Pharmaceutical Composition Comprising an Anti-IL-6 Receptor Antibody
#320Compositions for treatment of disorders
#321IN SITU SPRAYED BIORESPONSIVE IMMUNOTHERAPEUTIC GEL FOR POST-SURGICAL TREATMENT
#322PURIFIED ANTIBODY COMPOSITION
#323VEGF Antagonist Formulations
#324STABLE ANTIBODY FORMULATION
#325High concentration antibody-containing liquid formulation
#326PHARMACEUTICAL FORMULATIONS OF MASKED ANTIBODIES
#327Anti-PD1 antibodies and their use as therapeutics and diagnostics
#328ANTI-PDL1 ANTIBODY FORMULATIONS
#329Pre-filled pharmaceutical package comprising a liquid formulation of a VEGF-antagonist
#330Stable liquid formula comprising anti-TNFa antibody, acetate buffer, and glycine
#331CSF-1R ANTIBODY FORMULATION
#332Composition of Concentrated Human Immunoglobulins
#333Liquid pharmaceutical composition
#334Prevention of disulfide bond reduction during recombinant production of polypeptides
#335Solution Formulations of Engineered Anti-IL-23p19 Antibodies
#336Pharmaceutical compositions containing anti-beta amyloid antibodies
#337METHODS OF PREPARING STABLE LIQUID THERAPEUTIC PROTEIN COMPOSITIONS
#338Antibodies for treatment of cancer expressing claudin 6
#339Methods of treating viral infections by administering an antibody preparation comprising IGG, IGA and IGM
#340FGF21 mimetic antibodies and uses thereof
#341Excipient compounds for biopolymer formulations
#342Antibody Formulations
#343Methods for purifying antibodies having reduced high molecular weight aggregates
#344STABLE AQUEOUS ANTIBODY FORMULATION
#345PROLACTIN RECEPTOR ANTIBODY FOR MALE AND FEMALE PATTERN HAIR LOSS
#346Protein formulations and methods of making same
#347LIQUID PHARMACEUTICAL COMPOSITION
#348EXCIPIENT COMPOUNDS FOR PROTEIN FORMULATIONS
#349Protein formulations and methods of making same
#350FORMULATION OF HUMAN ANTIBODIES FOR TREATING TNF-ALPHA ASSOCIATED DISORDERS
#351Pharmaceutical compositions
#352AQUEOUS PHARMACEUTICAL FORMULATION COMPRISING ANTI-PD-L1 ANTIBODY AVELUMAB
#353PROCESS FOR CONCENTRATION OF ANTIBODIES AND THERAPEUTIC PRODUCTS THEREOF
#354Prevention of disulfide bond reduction during recombinant production of polypeptides
#355Antibody compositions
#356SUBCUTANEOUS HER2 ANTIBODY FORMULATIONS
#357Coated egg yolk cores, methods of making and methods of use thereof
#358Citrate buffered VEGF antagonist formulations
#359Antibody Formulations and Methods
#360ANTIBODY AND PROTEIN FORMULATIONS
#361PHARMACEUTICAL FORMULATIONS
#362Method of monomerisation of recombinant antibody molecules
#363Stabilized formulations containing anti-PCSK9 antibodies
#364Anti-PD-L1 antibodies and uses thereof
#365Formulations of antibody molecules to influenza virus
#366Methods for treatment using anti-alpha4beta7 antibody
#367Methods for quantitating individual antibodies from a mixture
#368Liquid pharmaceutical composition
#369STABLE AQUEOUS ANTI-TAU ANTIBODY FORMULATIONS
#370Liquid pharmaceutical composition
#371IMMUNE MOTIFS IN PRODUCTS FROM DOMESTIC ANIMALS
#372Composition and methods for stabilizing liquid protein formulations
#373Pre-filled plastic syringe containing a VEGF antagonist
#374ANTI-CD3 ANTIBODY FORMULATIONS
#375STABLE ANTI-PD-1 ANTIBODY PHARMACEUTICAL PREPARATION AND APPLICATION THEREOF IN MEDICINE
#376ETANERCEPT FORMULATIONS STABILIZED WITH XYLITOL
#377LIQUID PHARMACEUTICAL COMPOSITION OF ADALIMUMAB
#378Method of treating diseases using an IL-17 receptor antibody formulation
#379Pharmaceutical formulations of FcRn inhibitors suitable for subcutaneous administration
#380Anti-CD40 antibody formulation delivery device
#381ANTIBODY FORMULATION
#382Stabilized liquid anti-RSV antibody formulations
#383METHOD FOR REDUCING THE RECONSTITUTION TIME OF SPRAY-DRIED PROTEIN FORMULATIONS
#384Stable Dual Variable Domain Immunoglobulin Protein Formulations
#385LIQUID IL-1 BETA ANTIBODY FORMULATION HAVING PH OF 5.5 TO 7.0
#386Formulation for anti-α4β7 antibody
#387METHODS OF INACTIVATING VIRAL CONTAMINANTS
#388IL-22 FC compositions
#389Prevention of disulfide bond reduction during recombinant production of polypeptides
#390Anti-RSV monoclonal antibody formulation
#391Anti-tryptase antibodies, compositions thereof, and uses thereof
#392Prevention of disulfide bond reduction during recombinant production of polypeptides
#393Humanized Antibodies Against Enterovirus 71
#394Carrier-binding agent compositions and methods of making and using the same
#395Crystalline antibody formulations
#396Methods of Controlling the Formation of Disulfide Bonds in Protein Solutions
#397STABLE, AQUEOUS FORMULATIONS OF ANTIBODIES THAT BIND IL5 RECEPTOR
#398Stabilized formulations containing anti-IL-33 antibodies
#399Anti-IL-36R antibody formulations
#400Stable protein solution formulation containing high concentration of an anti-VEGF antibody
#401Methods and apparatus for false positive minimization in facial recognition applications
#402STABILIZED PROTEIN GEL PREPARATION
#403Methods and compositions related to antibody fragments that bind to tumor-associated glycoprotein 72 (TAG-72)
#404High concentration protein formulations with reduced viscosity
#405ANTIBODY-DRUG CONJUGATE LYOPHILISED FORMULATION
#406USE OF TRYPTOPHAN DERIVATIVES FOR PROTEIN FORMULATIONS
#407Formulations of antibody molecules to dengue virus
#408Methods for preventing disulfide bond reduction in cell culture harvest
#409Anti-epidermal growth factor receptor (EGFR) antibodies
#410Pharmaceutical formulations and methods of use thereof
#411BLyS antibody formulation
#412Stable IGG4 Based Binding Agent Formulations
#413Anti-PD1 antibodies and their use as therapeutics and diagnostics
#414Formulations with reduced degradation of polysorbate
#415IMMUNOGLOBULIN PURIFICATION
#416Methods of treating ulcerative colitis
#417Combination therapy comprising nivolumab and ipilimumab
#418TRKB OR TRKC AGONIST COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC CONDITIONS
#419FORMULATIONS OF ANTIBODY MOLECULES TO INFLUENZA VIRUS
#420Formulation for stabilizing bio-therapeutics
#421ANTIBODY FORMULATIONS
#422ANTIBODY FORMULATIONS
#423Method for preparing a composition comprising highly concentrated antibodies by ultrafiltration
#424Saposin-A derived peptides and uses thereof
#425IMMUNOCONJUGATES WITH OPTIMIZED LINKERS AND ORIENTATION
#426Antibodies of the class IGG4
#427Methods directed to crystalline biomolecules
#428High concentration protein formulation
#429LIQUID PHARMACEUTICAL COMPOSITION
#430ION EXCHANGE CHROMATOGRAPHY WITH IMPROVED SELECTIVITY FOR THE SEPARATION OF POLYPEPTIDE MONOMERS, AGGREGATES AND FRAGMENTS BY MODULATION OF THE MOBILE PHASE
#431Stable formulations of programmed death receptor 1 (PD-1) antibodies and methods of use thereof
#432STABILIZATION OF AQUEOUS COMPOSITIONS OF PROTEINS WITH DISPLACEMENT BUFFERS
#433ANTIBODY FORMULATIONS AND METHODS
#434Stabilized aqueous antibody compositions
#435IMPROVED METHODS FOR ENHANCING ANTIBODY PRODUCTIVITY IN MAMMALIAN CELL CULTURE AND MINIMIZING AGGREGATION DURING DOWNSTREAM, FORMULATION PROCESSES AND STABLE ANTIBODY FORMULATIONS OBTAINED THEREOF
#436ANTIBODY DRUG CONJUGATES
#437PROTEIN AQUEOUS SUSPENSION PREPARATION
#438Viscosity-reducing compounds for protein formulations
#439Treatment of intestinal dysbiosis with immunoglobin
#440AQUEOUS FORMULATION AND IN-SYRINGE AQUEOUS FORMULATION, AND ANTIBODY PROTEIN DEAGGREGATION AGENT AND ANTIBODY PROTEIN DEAGGREGATION METHOD
#441Liquid pharmaceutical composition
#442High concentration antibody-containing liquid formulation
#443PD-L1 antibody pharmaceutical composition and use thereof
#444STABILIZED ANTIBODY PROTEIN SOLUTIONS
#445ANTIBODY FORMULATION
#446Immunoglobulin preparation and storage system for an immunoglobulin preparation
#447N-acetylated and non-acetylated dipeptides containing arginine to reduce the viscosity of viscous compositions of therapeutic polypeptides
#448Room temperature stable lyophilized protein
#449Method for treatment of an IL-17A-mediated disease through antibody administration specific to human IL-17A
#450STABLE FORMULATIONS OF HUMANIZED ANTI-TAU ANTIBODY
#451COMPOSITIONS AND METHODS USEFUL FOR STABILIZING PROTEIN-CONTAINING FORMULATIONS
#452STABILIZED ANTIBODY PROTEIN SOLUTIONS
#453STABILIZED ANTIBODY SOLUTIONS
#454Liquid pharmaceutical composition
#455AQUEOUS ANTI-PD-L1 ANTIBODY FORMULATION
#456Formulations of VEG antagonist fusion proteins and method of manufacturing them
#457COMPOSITIONS COMPRISING COFORMULATION OF ANTI-PD-L1 AND ANTI-CTLA-4 ANTIBODIES
#458STABLE FORMULATIONS FOR ANTI-CD19 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES
#459AQUEOUS PHARMACEUTICAL FORMULATIONS
#460Anti-tryptase antibodies, compositions thereof, and uses thereof
#461Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodies
#462METHODS OF TREATING DISEASES
#463Pharmaceutical preparation stably comprising CD147 monoclonal antibody
#464HIGH CONCENTRATION ANTIBODY AND PROTEIN FORMULATIONS
#465PROTEIN FORMULATIONS AND METHODS OF MAKING SAME
#466Aglycosylated antibody Fc region for treating cancer
#467Stable liquid formula having an anti-TNFalpha antibody, acetate buffer and glycine
#468Etanercept formulations stabilized with sodium chloride
#469ANTIBODY FORMULATIONS
#470Etanercept Formulations Stabilized with Sodium Chloride
#471Subcutaneous formulations of anti-CD38 antibodies and their uses
#472Human anti-IL-33 neutralizing monoclonal antibody
#473ETANERCEPT FORMULATIONS STABILIZED WITH MEGLUMINE
#474Stabilized radio-labeled anti-CD45 immunoglobulin compositions
#475FORMULATIONS OF ANTIBODY
#476Etanercept Formulations Stabilized with Sodium Chloride
#477Etanercept Formulations Stabilized with Sodium Chloride
#478Etanercept Formulations Stabilized with Sodium Chloride
#479Composition for treatment of disorders
#480Method of reducing formation of etanercept aggregates or fragments
#481Purified antibody composition
#482Methods of Treating Multiple Myeloma
#483Stable aqueous etanercept composition
#484Method of reducing formation of etanercept aggregates or fragments
#485Stable aqueous etanercept composition
#486Method of Reducing Formation of Etanercept Aggregates or Fragments
#487Stabilized formulations containing anti-PCSK9 antibodies
#488Humanized antibodies with increased stability
#489Viscosity-reducing excipient compounds for protein formulations
#490Liquid pharmaceutical composition
#491STABILIZED ANTIBODY COMPOSITIONS
#492Antibody formulations
#493Stable pharmaceutical formulation
#494FORMULATION FOR ANTI-ALPHA4BETA7 ANTIBODY AND METHODS OF TREATMENT
#495Process for reducing subvisible particles in a pharmaceutical formulation
#496REDUCED-VISCOSITY CONCENTRATED PROTEIN FORMULATIONS
#497Liquid pharmaceutical composition comprising an anti-IL-6 receptor antibody
#498Hemostatic material, preparation method thereof and pharmaceutical composition containing the same
#499Etanercept formulations stabilized with amino acids
#500Compositions and methods for stabilizing protein-containing formulations
#501A Novel Method for Stabilization of a Biopharmaceutical Drug Product During Processing
#502Method for producing low viscous and highly concentrated biopharmaceutical drug products in liquid formulation
#503Human CD3 binding antibody
#504HIGH CONCENTRATION ANTI-TNFalpha ANTIBODY LIQUID FORMULATIONS
#505STABLE, AQUEOUS FORMULATIONS OF ANTIBODIES THAT BIND IL5 RECEPTOR
#506Anti-BAFFR antibody formulations and methods of use thereof
#507ANTI-VLA1 (CD49A) ANTIBODY PHARMACEUTICAL COMPOSITIONS
#508Stabilized radiolabeled anti-CD45 immunoglobulin compositions
#509Methods for quantitating individual antibodies from a mixture
#510Etanercept formulations stabilized with xylitol
#511Antibody formulations
#512Anti-CD40 antibodies for use in treatment of Sjögren's syndrome
#513Anti-CD40 antibody formulation
#514Pharmaceutical composition comprising bispecific antibody constructs for improved storage and administration
#515Nucleic acids encoding binding members to TNF alpha
#516Prevention of disulfide bond reduction during recombinant production of polypeptides
#517Method for suppressing aggregation of polypeptide
#518ETAR ANTIBODY, AND PHARMACEUTICAL COMPOSITIONS AND USE THEREOF
#519Crystalline antibody formulations
#520High concentration immunoglobulin composition for pharmaceutical application
#521Methods and formulations for treating vascular eye diseases using aflibercept and nesvacumab
#522Pharmaceutical composition comprising anti-human TSLP receptor antibody
#523Novel Formulations Which Stabilize Low Dose Antibody Compositions
#524ANTIBODY FORMULATIONS CONTAINING AMINO ACIDS
#525Method to produce a highly concentrated immunoglobulin preparation for subcutaneous use
#526Methods of reducing particle formation and compositions formed thereby
#527Pharmaceutical formulations
#528FORMULATION FOR ANTI-ALPHA4BETA7 ANTIBODY
#529PHARMACEUTICAL FORMULATIONS OF TNF-ALPHA ANTIBODIES
#530Stable aqueous formulations of adalimumab
#531Stable aqueous formulations of adalimumab
#532Stable aqueous formulations of adalimumab
#533Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Cysteinyl-tRNA synthetase
#534PROTEIN PURIFICATION METHODS TO REDUCE ACIDIC SPECIES
#535Stable aqueous formulations of adalimumab
#536Anti-CD137 molecules and use thereof
#537Binding members to PD-L1
#538Excipient compounds for protein processing
#539FORMULATION OF HUMAN ANTIBODIES FOR TREATING TNF-ALPHA ASSOCIATED DISORDERS
#540MODIFIED CELLS FOR IMMUNOTHERAPY
#541IL-6 ANTAGONIST FORMULATIONS AND USES THEREOF
#542OPTIMIZED RATIOS OF AMINO ACIDS AND SUGARS AS AMORPHOUS STABILIZING COMPOUNDS IN PHARMACEUTICAL COMPOSITIONS CONTAINING HIGH CONCENTRATIONS OF PROTEIN-BASED THERAPEUTIC AGENTS
#543Coated egg yolk cores, methods of making and methods of use thereof
#544FGF21 mimetic antibodies and uses thereof
#545Stable liquid formulations of recombinant fusion proteins
#546ANTI-DLL4/VEGF DUAL VARIABLE DOMAIN IMMUNOGLOBULIN AND USES THEREOF
#547Formulation for antibody and drug conjugate thereof
#548Buffer formulations for enhanced antibody stability
#549High concentration antibody formulations
#550Pharmaceutical formulations and methods of making the same
#551Hypercompressed pharmaceutical formulations
#552STABLE FORMULATIONS OF IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS
#553Antibodies for treatment of cancer expressing claudin 6
#554Antibody formulations
#555Pre-filled pharmaceutical package comprising a liquid formulation of a VEGF-antagonist
#556Aqueous pharmaceutical formulation comprising anti-PD-L1 antibody Avelumab
#557PROTEIN SUSTAINED-RELEASE INJECTABLE FORMULATION
#558IG1 AND THE THERAPEUTIC USE THEREOF
#559Anti-PCSK9 antibodies and uses thereof
#560FORMULATIONS OF SINGLE DOMAIN ANTIGEN BINDING MOLECULES
#561IL-17 receptor antibody formulation
#562FORMULATION FOR ANTI-ALPHA4BETA7 ANTIBODY
#563Solution preparation containing stabilized antibody
#564FORMULATION OF HUMAN ANTIBODIES FOR TREATING TNF-ALPHA ASSOCIATED DISORDERS
#565Stable anti-PD-1 antibody pharmaceutical preparation and application thereof in medicine
#566METHODS OF TREATING DISEASES
#567High concentration protein formulations with reduced viscosity
#568Anti-CGRP/anti-IL-23 bispecific antibodies and uses thereof
#569IgG, IgA and IgM antibody preparations, method of making and method of use in treatment
#570Formulations with reduced oxidation
#571Stable aqueous formulations of adalimumab
#572Stable aqueous formulations of adalimumab
#573Stable aqueous formulations of adalimumab
#574Stable aqueous formulations of adalimumab
#575Methods for treating ocular diseases with brolucizumab
#576LIQUID PHARMACEUTICAL COMPOSITION
#577Subcutaneous HER2 antibody formulations
#578METHODS OF TREATING INFLAMMATORY BOWEL DISEASE
#579ANTIBODY FORMULATION
#580Antibody formulations
#581Anti-CD40 Antibody Formulations
#582Pharmaceutical product with increased stability comprising immunoglobulins
#583Concentrated protein formulations and uses thereof
#584Molecules with Reduced Effector Function and Extended Half-Lives, Compositions, and Uses Thereof
#585Pharmaceutical formulations and methods of making the same
#586PROTEIN COMPOSITIONS AND USE THEREOF
#587Methods of preventing and removing trisulfide bonds
#588Anti-BAFFR antibody therapeutic formulations
#589Anti-PD1 antibodies and their use as therapeutics and diagnostics
#590Anti-RSV monoclonal antibody formulation
#591STABILIZATION OF IMMUNOGLOBULINS THROUGH AQUEOUS FORMULATION WITH HISTIDINE AT WEAK ACIDIC TO NEUTRAL PH
#592LIQUID ANTIBODY FORMULATION WITH IMPROVED AGGREGATION PROPERTIES
#593Human CD3 binding antibody
#594Low-viscosity, high concentration evolocumab formulations and methods of making the same
#595Antibody formulations and methods
#596Anti-tryptase antibodies, compositions thereof, and uses thereof
#597Stabilized liquid anti-RSV antibody formulations
#598Methods and compositions for therapeutic agents
#599Subcutaneous anti-HER2 Antibody Formulations and Uses Thereof
#600ANTIBODY FORMULATIONS